🔗

Mappings

MONDO

MONDO:0012960 intellectual disability, autosomal dominant 5

MONDO:0012960 (MRD5) is the SYNGAP1 disorder concept; "SYNGAP1-related developmental and epileptic encephalopathy" is an exact synonym.

👪

Inheritance

1

Autosomal dominant inheritance HP:0000006

SYNGAP1-related disorder is inherited in an autosomal dominant manner; most affected individuals have a de novo pathogenic variant.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"SYNGAP1-ID is inherited in an autosomal dominant manner."

GeneReviews establishes autosomal dominant inheritance.

?

Discussions and Knowledge Gaps

3

How much of the SYNGAP1-related phenotype is fixed by the developmental shortening of the critical period versus reversible in adulthood, and what is the treatment window for the emerging SYNGAP1-upregulating and gene therapies?

KNOWLEDGE GAP OPEN gap_syngap1_developmental_window_adult_reversibility

Attached to

pathophysiology#Premature Excitatory Synapse and Dendritic Spine Maturation pathophysiology#Impaired Cognitive Development

SynGAP paces synaptic maturation, and its loss causes premature spine maturation that shortens the developmental critical period, implying an early and possibly fixed contribution to intellectual disability. Yet re-expression of SynGAP in adult mice improves memory and seizure measures, suggesting some deficits remain reversible after development. How much of the human phenotype can be recovered by restoring SYNGAP1 dosage after diagnosis, and how wide the therapeutic window is, is decisive for the design and timing of the antisense-oligonucleotide and gene therapies now entering development.

Proposed experiments

Timed SYNGAP1 restoration across development and adulthood

timed gene-restoration experiment

exp_syngap1_timed_restoration

In a conditional Syngap1 model, restore SynGAP at graded ages and measure recovery of network excitability, seizure susceptibility, and cognitive/behavioral endpoints as a function of restoration age.

Readouts

Recovery by restoration age

pathophysiology#Impaired Cognitive Development

behavioral assay electroencephalography

Direction: POSITIVE

Controls

Never-restored and wild-type

Matched never-restored mutants and wild-type controls.

Decision criterion

A treatment window is supported if recovery declines with later restoration age; broad reversibility is supported if late restoration still rescues endpoints.

Would support

pathophysiology#Impaired Cognitive Development

Show evidence (1 reference)

PMID:31025938 SUPPORT Model Organism

"Adult restoration of SynGAP protein improved behavioral and electrophysiological measures of memory and seizure."

Demonstrates partial adult reversibility in a mouse model, framing the open question of the human treatment window.

Can boosting expression of the single functional SYNGAP1 allele (an upregulating antisense-oligonucleotide or gene-therapy strategy) restore sufficient SynGAP to be disease-modifying, and how precisely must dosage be controlled given the gene's dosage sensitivity?

EMERGING HYPOTHESIS OPEN gap_syngap1_dosage_upregulation_therapy

Attached to

pathophysiology#SYNGAP1 Haploinsufficiency

SYNGAP1 disease is a haploinsufficiency: one functional copy is not enough. Because too little SynGAP causes disease, therapies that upregulate the remaining allele or add gene copies are attractive and are entering development, but SynGAP dosage is tightly constrained, and overshooting could have its own consequences. Whether dosage can be restored into a therapeutic range, and what biomarker confirms it, is the open translational question for this actively developing pipeline.

Proposed experiments

SYNGAP1 dosage-restoration therapeutic window

dosage-titration experiment

exp_syngap1_dosage_restoration_window

In patient iPSC-derived neurons and Syngap1 mice, titrate SYNGAP1 upregulation and measure the relationship between restored SynGAP level and normalization of synaptic and network phenotypes, defining the effective and safe dosage range.

Readouts

Phenotype normalization versus SynGAP level

pathophysiology#SYNGAP1 Haploinsufficiency

multielectrode array recording immunoblot assay

Direction: POSITIVE

Controls

Untreated haploinsufficient and wild-type

Matched untreated mutant and wild-type references.

Decision criterion

An upregulation strategy is supported if restoring SynGAP toward normal levels normalizes synaptic and network phenotypes within a controllable dosage range.

Would support

pathophysiology#SYNGAP1 Haploinsufficiency

Show evidence (1 reference)

PMID:39807402 SUPPORT Other

"one of many rare monogenic brain disorders without disease-modifying treatments"

Frames the current absence of disease-modifying therapy and the active dosage-restoration pipeline that this hypothesis concerns.

Which downstream consequence of SynGAP loss (excitatory synapse over-strengthening, AMPA-receptor mis-trafficking, or inhibitory-circuit involvement) drives which arm of the phenotype - the generalized epilepsy, the intellectual disability, and the autism - and does the consistent developmental-delay-before-seizures sequence reflect distinct mechanisms?

KNOWLEDGE GAP OPEN gap_syngap1_mechanism_to_phenotype

Attached to

pathophysiology#Cortical Excitation-Inhibition Imbalance pathophysiology#Impaired Cognitive Development

SynGAP haploinsufficiency perturbs excitatory synapse maturation, AMPA-receptor trafficking, and circuit excitation/inhibition balance, and the disorder combines epilepsy, intellectual disability, and autism. Developmental delay reliably precedes seizure onset. Whether these features share one substrate or arise from separable mechanisms - and whether targeting one (e.g., normalizing excitatory strength) would help all three - is unresolved and shapes what a therapy should be measured against.

Proposed experiments

Cell-type-specific contributions to epilepsy versus cognition

cell-type-restricted manipulation experiment

exp_syngap1_celltype_specific_contributions

Using cell-type-restricted Syngap1 manipulation (excitatory neurons versus interneurons), test which population's dysfunction produces the seizures versus the cognitive and autistic phenotypes.

Readouts

Phenotype by targeted cell type

pathophysiology#Cortical Excitation-Inhibition Imbalance

electroencephalography behavioral assay

Direction: POSITIVE

Controls

Pan-neuronal and wild-type

Pan-neuronal manipulation and wild-type as references.

Decision criterion

A feature is assigned to a cell type if restricting the SynGAP deficit to that population reproduces it while sparing the others.

Would support

pathophysiology#Cortical Excitation-Inhibition Imbalance

Show evidence (1 reference)

PMID:30541864 SUPPORT Human Clinical

"SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."

Characterizes the distinctive combined phenotype whose mechanistic partitioning is the open question.

⚙

Pathophysiology

9

SYNGAP1 Haploinsufficiency

A heterozygous loss-of-function variant in SYNGAP1 (or a 6p21.3 deletion encompassing it), usually de novo, reduces functional SynGAP protein to roughly half. This node captures the single concept of the initiating haploinsufficiency.

SYNGAP1 hgnc:11497

Downstream

Reduced SynGAP at the Excitatory Postsynaptic Density Reduced SYNGAP1 dosage lowers SynGAP protein at excitatory synapses.

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"The diagnosis of SYNGAP1-ID is established in a proband with developmental delay or intellectual disability in whom molecular genetic testing identifies either a heterozygous pathogenic variant in SYNGAP1 (~89%) or a deletion of 6p21.3 (~11%)."

GeneReviews establishes heterozygous SYNGAP1 loss-of-function variants (or 6p21.3 deletion) as the molecular cause.

Reduced SynGAP at the Excitatory Postsynaptic Density

SynGAP is a Ras/Rap GTPase-activating protein highly concentrated at the postsynaptic density of excitatory (glutamatergic) synapses, where it restrains synaptic Ras signaling. Its reduction removes this brake. This node captures the single concept of the synaptic protein deficit.

Glutamatergic neuron CL:0000679

GTPase activator activity GO:0005096 ↓ DECREASED

Downstream

Dysregulated Ras Signaling and AMPA Receptor Trafficking Loss of SynGAP GAP activity dysregulates postsynaptic Ras signaling and AMPA-receptor trafficking.

Show evidence (1 reference)

PMID:26912996 SUPPORT Other

"SYNGAP1 is a negative regulator of Ras, Rap and of AMPA receptor trafficking to the postsynaptic membrane"

Establishes SynGAP as a synaptic brake that negatively regulates Ras/Rap signaling and AMPA-receptor trafficking; its loss disinhibits this pathway.

Dysregulated Ras Signaling and AMPA Receptor Trafficking

Without adequate SynGAP, Ras-ERK signaling at the synapse is disinhibited, increasing insertion of AMPA-type glutamate receptors and strengthening excitatory transmission. This node captures the single concept of the signaling and receptor-trafficking derangement.

Glutamatergic neuron CL:0000679

Regulation of Ras protein signal transduction GO:0046578 ↑ INCREASED

Downstream

Premature Excitatory Synapse and Dendritic Spine Maturation Enhanced Ras signaling and AMPA-receptor insertion accelerate excitatory synapse and dendritic spine maturation.

Premature Excitatory Synapse and Dendritic Spine Maturation

SynGAP normally paces the maturation of dendritic spines and excitatory synapses; its loss causes premature, accelerated maturation and an excess of strengthened excitatory synapses during development. This node captures the single concept of the accelerated synaptic maturation defect.

Glutamatergic neuron CL:0000679

Dendritic spine development GO:0060996 ↕ DYSREGULATED

Downstream

Cortical Excitation-Inhibition Imbalance Excess excitatory synaptic strength shifts cortical circuits toward excitation.

Impaired Cognitive Development Mistimed synaptic maturation disrupts the circuit refinement needed for cognition.

Show evidence (1 reference)

PMID:23141534 SUPPORT Model Organism

"In the SYNGAP1 mouse model of ID/ASD, we found that dendritic spine synapses develop prematurely during the early postnatal period."

The observation this node is built on - accelerated rather than merely abnormal spine maturation - measured in the Syngap1 heterozygous mouse. The same study found that inducing the mutation after the critical window had minimal effect, which is why the node is framed developmentally.

Cortical Excitation-Inhibition Imbalance

The net effect is a shift of cortical circuits toward excitation over inhibition, lowering seizure threshold. This node captures the single concept of the excitation-inhibition imbalance and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

Neuronal Network Hyperexcitability The imbalance produces hyperexcitable, hypersynchronous networks.

Neuronal Network Hyperexcitability

Cortical networks become hyperexcitable and prone to hypersynchronous, generalized discharges. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

Generalized Epilepsy Hypersynchronous networks generate the generalized seizures of the disorder.

Show evidence (1 reference)

PMID:23141534 SUPPORT Model Organism

"Premature spine maturation dramatically enhanced excitability in the developing hippocampus, which corresponded with the emergence of behavioral abnormalities."

Ties the upstream synaptic defect to measured hyperexcitability in the same animals, which is the edge this node sits on. Hippocampal rather than cortical, and in mouse, so it supports the mechanism without standing in for human cortical recordings.

Generalized Epilepsy

Most affected individuals develop generalized epilepsy, and a characteristic subset has myoclonic-astatic epilepsy (Doose syndrome) or epilepsy with myoclonic absences. This node captures the single concept of the seizure endpoint and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"a subset of individuals with epilepsy have myoclonic astatic epilepsy (Doose syndrome) or epilepsy with myoclonic absences."

GeneReviews documents the characteristic generalized epilepsy including the myoclonic-astatic (Doose) subset.

Impaired Cognitive Development

Developmental delay and intellectual disability, moderate to severe in most, are essentially universal. This node captures the single concept of the cognitive outcome.

Neuron CL:0000540

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"is characterized by developmental delay (DD) or intellectual disability (ID) (100% of affected individuals), generalized epilepsy (~84%), and autism spectrum disorder (ASD) and other behavioral abnormalities"

GeneReviews documents developmental delay/intellectual disability in 100% of affected individuals.

Autism and Behavioral Abnormalities

About half of affected individuals have autism spectrum disorder or other behavioral abnormalities, including stereotypies. This node captures the single concept of the neurobehavioral outcome.

Neuron CL:0000540

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Digestive 1

Feeding Difficulties HP:0011968

Musculoskeletal 1

Hypotonia HP:0001252

Nervous System 7

Global Developmental Delay HP:0001263

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"is characterized by developmental delay (DD) or intellectual disability (ID) (100% of affected individuals), generalized epilepsy (~84%), and autism spectrum disorder (ASD) and other behavioral abnormalities"

GeneReviews documents DD/ID in 100% of affected individuals.

Intellectual Disability HP:0001249

Absence Seizures Generalized non-motor (absence) seizure HP:0002121

Autistic Behavior HP:0000729

Eyelid Myoclonia with Absences FREQUENT Absence seizure with eyelid myoclonia HP:0011149

Show evidence (1 reference)

PMID:30541864 SUPPORT Human Clinical

"Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%."

Vlaskamp cohort quantifies eyelid myoclonia with absences in 65% of patients.

Ataxia FREQUENT HP:0001251

Show evidence (1 reference)

PMID:30541864 SUPPORT Human Clinical

"high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%)."

Vlaskamp cohort quantifies ataxia or gait abnormalities in 51% of patients.

Sleep Disturbance FREQUENT HP:0002360

Show evidence (1 reference)

PMID:30541864 SUPPORT Human Clinical

"high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%)."

Vlaskamp cohort quantifies sleeping problems in 62% of patients.

Other 5

Generalized-Onset Seizures HP:0002197

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"a subset of individuals with epilepsy have myoclonic astatic epilepsy (Doose syndrome) or epilepsy with myoclonic absences."

GeneReviews documents the generalized epilepsy and its Doose subset.

Myoclonic Seizures HP:0032794

Motor Stereotypies Motor stereotypy HP:0000733

Eating-Induced Seizures OCCASIONAL HP:0020208

Show evidence (1 reference)

PMID:30541864 SUPPORT Human Clinical

"Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%."

Vlaskamp cohort quantifies eating-triggered seizures in 25% of patients.

High Pain Threshold FREQUENT Pain insensitivity HP:0007021

Show evidence (1 reference)

PMID:30541864 SUPPORT Human Clinical

"high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%)."

Vlaskamp cohort quantifies high pain threshold in 72% of patients.

🧬

Genetic Associations

1

SYNGAP1

Gene: SYNGAP1 hgnc:11497 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"The diagnosis of SYNGAP1-ID is established in a proband with developmental delay or intellectual disability in whom molecular genetic testing identifies either a heterozygous pathogenic variant in SYNGAP1 (~89%) or a deletion of 6p21.3 (~11%)."

GeneReviews documents the SYNGAP1 variant classes and their proportions.

💊

Medical Actions

2

Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Epilepsy is managed with antiseizure medications; about half of affected individuals respond to a single agent while the remainder are pharmacoresistant. No SYNGAP1-specific ASM guideline exists.

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"In about 50% of affected individuals, the epilepsy responds to a single ASM; in the remainder it is pharmacoresistant."

GeneReviews documents the mixed antiseizure-medication response.

Developmental and Behavioral Supportive Care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Developmental delay/intellectual disability and autism are managed with standard developmental, educational, and behavioral interventions; nasogastric/gastrostomy feeding may be needed for significant feeding issues.

🔬

Diagnosis

1

SYNGAP1 Molecular Genetic Testing

Diagnosis is established by molecular genetic testing identifying a heterozygous pathogenic SYNGAP1 variant (~89%) or a 6p21.3 deletion (~11%) in a proband with developmental delay or intellectual disability.

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"The diagnosis of SYNGAP1-ID is established in a proband with developmental delay or intellectual disability in whom molecular genetic testing identifies either a heterozygous pathogenic variant in SYNGAP1 (~89%) or a deletion of 6p21.3 (~11%)."

GeneReviews establishes molecular genetic testing as the confirmatory diagnostic method.

📊

Prevalence

1

Worldwide

Cases In Literature Rare

No precise population rate is established, but SYNGAP1-related disorder is recognized as one of the more common single-gene causes of intellectual disability with epilepsy; as of the GeneReviews summary more than 50 affected individuals had been reported, and modern registries include substantially larger cohorts.

Show evidence (1 reference)

PMID:30789692 SUPPORT Human Clinical

"To date more than 50 individuals with SYNGAP1-ID have been reported."

Provides a literature case count; no normalized population rate is asserted.

📊

Related Datasets

1

Epigenetic Modulation to perturb the SYNGAP1 Intellectual Disability (ID) that ameliorates synaptic and behavioural deficits geo:GSE252400

Whole-hippocampal RNA sequencing across six arms - wild-type and Syngap1+/- mice each given saline, carrier nanosphere alone, or the nanosphere-conjugated p300/CBP acetyltransferase activator CSP-TTK21 - profiled after Morris water maze training. The design carries both the haploinsufficiency comparison and a pharmacological rescue arm, so it is usable for the SYNGAP1 loss-of-function transcriptome and for testing whether that transcriptome is reversible in the adult animal.

house mouse BULK RNA SEQ n=18

PMID:39878322

Found by a targeted GEO DataSets search for SYNGAP1; accession and metadata verified against NCBI E-utilities on 2026-08-27. Title, sample count, and organism are GEO's own values. Model-organism data - the gene descriptor is the human HGNC record for the disease gene; the mouse orthologue is Syngap1. GEO lists no linked PMID on the series; the publication recorded here is the paper reporting this experiment, matched on the series summary and design. This is the only SYNGAP1 disease dataset in GEO as of 2026-08-27 - a search across all fields returns seven other series, none of which studies SYNGAP1 loss of function.

{ }

Source YAML

click to show

name: SYNGAP1-Related Developmental and Epileptic Encephalopathy
creation_date: "2026-07-17T00:00:00Z"
category: Mendelian
description: >-
  SYNGAP1-related developmental and epileptic encephalopathy (also called
  SYNGAP1-related intellectual disability, MRD5) is an autosomal dominant
  neurodevelopmental disorder caused by haploinsufficiency of SYNGAP1, which
  encodes SynGAP - a Ras/Rap GTPase-activating protein highly enriched at
  excitatory postsynaptic densities. Essentially all affected individuals have
  developmental delay or intellectual disability; most (~84%) have generalized
  epilepsy, and about half have autism spectrum disorder or other behavioral
  problems. A characteristic subset has myoclonic-astatic epilepsy (Doose
  syndrome) or epilepsy with myoclonic absences. Because SynGAP restrains
  Ras-ERK signaling and AMPA-receptor insertion during synapse maturation, its
  reduction accelerates excitatory synapse maturation and tips cortical circuits
  toward excitation. Most cases arise de novo.
parents:
- Epilepsy
- Neurodevelopmental Disorder
- Neurological Disease
synonyms:
- SYNGAP1-related intellectual disability
- SYNGAP1-ID
- Intellectual disability, autosomal dominant 5
- MRD5
- Epilepsy due to SYNGAP1 mutations
disease_term:
  preferred_term: SYNGAP1-related developmental and epileptic encephalopathy
  term:
    id: MONDO:0012960
    label: intellectual disability, autosomal dominant 5
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0012960
      label: intellectual disability, autosomal dominant 5
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0012960 (MRD5) is the SYNGAP1 disorder concept; "SYNGAP1-related
      developmental and epileptic encephalopathy" is an exact synonym.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    SYNGAP1-related disorder is inherited in an autosomal dominant manner; most
    affected individuals have a de novo pathogenic variant.
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SYNGAP1-ID is inherited in an autosomal dominant manner."
    explanation: GeneReviews establishes autosomal dominant inheritance.
pathophysiology:
- name: SYNGAP1 Haploinsufficiency
  description: >-
    A heterozygous loss-of-function variant in SYNGAP1 (or a 6p21.3 deletion
    encompassing it), usually de novo, reduces functional SynGAP protein to
    roughly half. This node captures the single concept of the initiating
    haploinsufficiency.
  role: trigger
  gene:
    preferred_term: SYNGAP1
    term:
      id: hgnc:11497
      label: SYNGAP1
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SYNGAP1-ID is established in a proband with developmental delay or intellectual disability in whom molecular genetic testing identifies either a heterozygous pathogenic variant in SYNGAP1 (~89%) or a deletion of 6p21.3 (~11%)."
    explanation: >-
      GeneReviews establishes heterozygous SYNGAP1 loss-of-function variants (or
      6p21.3 deletion) as the molecular cause.
  downstream:
  - target: Reduced SynGAP at the Excitatory Postsynaptic Density
    causal_link_type: DIRECT
    description: >-
      Reduced SYNGAP1 dosage lowers SynGAP protein at excitatory synapses.
- name: Reduced SynGAP at the Excitatory Postsynaptic Density
  description: >-
    SynGAP is a Ras/Rap GTPase-activating protein highly concentrated at the
    postsynaptic density of excitatory (glutamatergic) synapses, where it
    restrains synaptic Ras signaling. Its reduction removes this brake. This
    node captures the single concept of the synaptic protein deficit.
  role: mediator
  cell_types:
  - preferred_term: Glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  molecular_functions:
  - preferred_term: GTPase activator activity
    term:
      id: GO:0005096
      label: GTPase activator activity
    modifier: DECREASED
  evidence:
  - reference: PMID:26912996
    reference_title: "SYNGAP1: Mind the Gap."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SYNGAP1 is a negative regulator of Ras, Rap and of AMPA receptor trafficking to the postsynaptic membrane"
    explanation: >-
      Establishes SynGAP as a synaptic brake that negatively regulates Ras/Rap
      signaling and AMPA-receptor trafficking; its loss disinhibits this
      pathway.
  downstream:
  - target: Dysregulated Ras Signaling and AMPA Receptor Trafficking
    causal_link_type: DIRECT
    description: >-
      Loss of SynGAP GAP activity dysregulates postsynaptic Ras signaling and
      AMPA-receptor trafficking.
- name: Dysregulated Ras Signaling and AMPA Receptor Trafficking
  description: >-
    Without adequate SynGAP, Ras-ERK signaling at the synapse is disinhibited,
    increasing insertion of AMPA-type glutamate receptors and strengthening
    excitatory transmission. This node captures the single concept of the
    signaling and receptor-trafficking derangement.
  role: mediator
  cell_types:
  - preferred_term: Glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: Regulation of Ras protein signal transduction
    term:
      id: GO:0046578
      label: regulation of Ras protein signal transduction
    modifier: INCREASED
  downstream:
  - target: Premature Excitatory Synapse and Dendritic Spine Maturation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Enhanced Ras signaling and AMPA-receptor insertion accelerate excitatory
      synapse and dendritic spine maturation.
- name: Premature Excitatory Synapse and Dendritic Spine Maturation
  description: >-
    SynGAP normally paces the maturation of dendritic spines and excitatory
    synapses; its loss causes premature, accelerated maturation and an excess of
    strengthened excitatory synapses during development. This node captures the
    single concept of the accelerated synaptic maturation defect.
  role: mediator
  cell_types:
  - preferred_term: Glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: Dendritic spine development
    term:
      id: GO:0060996
      label: dendritic spine development
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:23141534
    reference_title: "Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In the SYNGAP1 mouse model of ID/ASD, we found that dendritic spine synapses develop prematurely during the early postnatal period."
    explanation: >-
      The observation this node is built on - accelerated rather than merely
      abnormal spine maturation - measured in the Syngap1 heterozygous mouse.
      The same study found that inducing the mutation after the critical window
      had minimal effect, which is why the node is framed developmentally.
  downstream:
  - target: Cortical Excitation-Inhibition Imbalance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Excess excitatory synaptic strength shifts cortical circuits toward
      excitation.
  - target: Impaired Cognitive Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Mistimed synaptic maturation disrupts the circuit refinement needed for
      cognition.
- name: Cortical Excitation-Inhibition Imbalance
  description: >-
    The net effect is a shift of cortical circuits toward excitation over
    inhibition, lowering seizure threshold. This node captures the single
    concept of the excitation-inhibition imbalance and conforms to the shared
    epilepsy final common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Neuronal Network Hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The imbalance produces hyperexcitable, hypersynchronous networks.
- name: Neuronal Network Hyperexcitability
  description: >-
    Cortical networks become hyperexcitable and prone to hypersynchronous,
    generalized discharges. This node captures the single concept of network
    hyperexcitability and conforms to the shared epilepsy final common pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:23141534
    reference_title: "Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Premature spine maturation dramatically enhanced excitability in the developing hippocampus, which corresponded with the emergence of behavioral abnormalities."
    explanation: >-
      Ties the upstream synaptic defect to measured hyperexcitability in the
      same animals, which is the edge this node sits on. Hippocampal rather
      than cortical, and in mouse, so it supports the mechanism without
      standing in for human cortical recordings.
  downstream:
  - target: Generalized Epilepsy
    causal_link_type: DIRECT
    description: >-
      Hypersynchronous networks generate the generalized seizures of the
      disorder.
- name: Generalized Epilepsy
  description: >-
    Most affected individuals develop generalized epilepsy, and a characteristic
    subset has myoclonic-astatic epilepsy (Doose syndrome) or epilepsy with
    myoclonic absences. This node captures the single concept of the seizure
    endpoint and conforms to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a subset of individuals with epilepsy have myoclonic astatic epilepsy (Doose syndrome) or epilepsy with myoclonic absences."
    explanation: >-
      GeneReviews documents the characteristic generalized epilepsy including
      the myoclonic-astatic (Doose) subset.
- name: Impaired Cognitive Development
  description: >-
    Developmental delay and intellectual disability, moderate to severe in most,
    are essentially universal. This node captures the single concept of the
    cognitive outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is characterized by developmental delay (DD) or intellectual disability (ID) (100% of affected individuals), generalized epilepsy (~84%), and autism spectrum disorder (ASD) and other behavioral abnormalities"
    explanation: >-
      GeneReviews documents developmental delay/intellectual disability in 100%
      of affected individuals.
- name: Autism and Behavioral Abnormalities
  description: >-
    About half of affected individuals have autism spectrum disorder or other
    behavioral abnormalities, including stereotypies. This node captures the
    single concept of the neurobehavioral outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
phenotypes:
- name: Global Developmental Delay
  description: Developmental delay is essentially universal.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is characterized by developmental delay (DD) or intellectual disability (ID) (100% of affected individuals), generalized epilepsy (~84%), and autism spectrum disorder (ASD) and other behavioral abnormalities"
    explanation: GeneReviews documents DD/ID in 100% of affected individuals.
- name: Intellectual Disability
  description: Intellectual disability, moderate to severe in most.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
- name: Generalized-Onset Seizures
  description: >-
    Generalized epilepsy affects most individuals; the Doose (myoclonic-astatic)
    pattern is characteristic.
  phenotype_term:
    preferred_term: Generalized-onset seizure
    term:
      id: HP:0002197
      label: Generalized-onset seizure
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a subset of individuals with epilepsy have myoclonic astatic epilepsy (Doose syndrome) or epilepsy with myoclonic absences."
    explanation: GeneReviews documents the generalized epilepsy and its Doose subset.
- name: Myoclonic Seizures
  description: Myoclonic seizures occur, including myoclonic absences.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
- name: Absence Seizures
  description: Absence (including myoclonic absence) seizures occur.
  phenotype_term:
    preferred_term: Absence seizure
    term:
      id: HP:0002121
      label: Generalized non-motor (absence) seizure
- name: Autistic Behavior
  description: Autism spectrum disorder affects about half of individuals.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
- name: Motor Stereotypies
  description: Stereotypic behaviors such as hand flapping occur.
  phenotype_term:
    preferred_term: Motor stereotypy
    term:
      id: HP:0000733
      label: Motor stereotypy
- name: Feeding Difficulties
  description: Feeding difficulties can be significant in some individuals.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
- name: Hypotonia
  description: Hypotonia is commonly present.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
- name: Eyelid Myoclonia with Absences
  description: >-
    Eyelid myoclonia with absences is a characteristic and frequent seizure
    type (~65%).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Absence seizure with eyelid myoclonia
    term:
      id: HP:0011149
      label: Absence seizure with eyelid myoclonia
  evidence:
  - reference: PMID:30541864
    reference_title: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%."
    explanation: Vlaskamp cohort quantifies eyelid myoclonia with absences in 65% of patients.
- name: Eating-Induced Seizures
  description: >-
    Seizures triggered by eating (reflex seizures) are a hallmark of the
    syndrome (~25%).
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Eating-induced seizure
    term:
      id: HP:0020208
      label: Eating-induced seizure
  evidence:
  - reference: PMID:30541864
    reference_title: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%."
    explanation: Vlaskamp cohort quantifies eating-triggered seizures in 25% of patients.
- name: High Pain Threshold
  description: >-
    A high pain threshold (reduced pain sensitivity) is a distinctive frequent
    feature (~72%).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: High pain threshold
    term:
      id: HP:0007021
      label: Pain insensitivity
  evidence:
  - reference: PMID:30541864
    reference_title: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%)."
    explanation: Vlaskamp cohort quantifies high pain threshold in 72% of patients.
- name: Ataxia
  description: Ataxia or gait abnormalities are frequent (~51%).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:30541864
    reference_title: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%)."
    explanation: Vlaskamp cohort quantifies ataxia or gait abnormalities in 51% of patients.
- name: Sleep Disturbance
  description: Sleep problems are frequent (~62%).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:30541864
    reference_title: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%)."
    explanation: Vlaskamp cohort quantifies sleeping problems in 62% of patients.
genetic:
- name: SYNGAP1
  gene_term:
    preferred_term: SYNGAP1
    term:
      id: hgnc:11497
      label: SYNGAP1
  relationship_type: CAUSATIVE
  notes: >-
    SYNGAP1 (6p21.32) encodes SynGAP, a synaptic Ras/Rap GTPase-activating
    protein. Disease is caused by heterozygous loss-of-function variants
    (~89%; nonsense, frameshift, splice, missense) or 6p21.3 deletions (~11%),
    acting by haploinsufficiency; most are de novo.
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SYNGAP1-ID is established in a proband with developmental delay or intellectual disability in whom molecular genetic testing identifies either a heterozygous pathogenic variant in SYNGAP1 (~89%) or a deletion of 6p21.3 (~11%)."
    explanation: GeneReviews documents the SYNGAP1 variant classes and their proportions.
diagnosis:
- name: SYNGAP1 Molecular Genetic Testing
  description: >-
    Diagnosis is established by molecular genetic testing identifying a
    heterozygous pathogenic SYNGAP1 variant (~89%) or a 6p21.3 deletion (~11%)
    in a proband with developmental delay or intellectual disability.
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SYNGAP1-ID is established in a proband with developmental delay or intellectual disability in whom molecular genetic testing identifies either a heterozygous pathogenic variant in SYNGAP1 (~89%) or a deletion of 6p21.3 (~11%)."
    explanation: GeneReviews establishes molecular genetic testing as the confirmatory diagnostic method.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: RARE
  notes: >-
    No precise population rate is established, but SYNGAP1-related disorder is
    recognized as one of the more common single-gene causes of intellectual
    disability with epilepsy; as of the GeneReviews summary more than 50
    affected individuals had been reported, and modern registries include
    substantially larger cohorts.
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date more than 50 individuals with SYNGAP1-ID have been reported."
    explanation: >-
      Provides a literature case count; no normalized population rate is
      asserted.
treatments:
- name: Antiseizure Medication
  description: >-
    Epilepsy is managed with antiseizure medications; about half of affected
    individuals respond to a single agent while the remainder are
    pharmacoresistant. No SYNGAP1-specific ASM guideline exists.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:30789692
    reference_title: "SYNGAP1-Related Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In about 50% of affected individuals, the epilepsy responds to a single ASM; in the remainder it is pharmacoresistant."
    explanation: GeneReviews documents the mixed antiseizure-medication response.
- name: Developmental and Behavioral Supportive Care
  description: >-
    Developmental delay/intellectual disability and autism are managed with
    standard developmental, educational, and behavioral interventions;
    nasogastric/gastrostomy feeding may be needed for significant feeding issues.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
datasets:
- accession: geo:GSE252400
  title: >-
    Epigenetic Modulation to perturb the SYNGAP1 Intellectual Disability (ID)
    that ameliorates synaptic and behavioural deficits
  description: >-
    Whole-hippocampal RNA sequencing across six arms - wild-type and
    Syngap1+/- mice each given saline, carrier nanosphere alone, or the
    nanosphere-conjugated p300/CBP acetyltransferase activator CSP-TTK21 -
    profiled after Morris water maze training. The design carries both the
    haploinsufficiency comparison and a pharmacological rescue arm, so it is
    usable for the SYNGAP1 loss-of-function transcriptome and for testing
    whether that transcriptome is reversible in the adult animal.
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 18
  genes:
  - preferred_term: SYNGAP1
    term:
      id: hgnc:11497
      label: SYNGAP1
  publication: PMID:39878322
  notes: >-
    Found by a targeted GEO DataSets search for SYNGAP1; accession and metadata
    verified against NCBI E-utilities on 2026-08-27. Title, sample count, and
    organism are GEO's own values. Model-organism data - the gene descriptor is
    the human HGNC record for the disease gene; the mouse orthologue is Syngap1.
    GEO lists no linked PMID on the series; the publication recorded here is the
    paper reporting this experiment, matched on the series summary and design.
    This is the only SYNGAP1 disease dataset in GEO as of 2026-08-27 - a search
    across all fields returns seven other series, none of which studies
    SYNGAP1 loss of function.
discussions:
- discussion_id: gap_syngap1_developmental_window_adult_reversibility
  prompt: >-
    How much of the SYNGAP1-related phenotype is fixed by the developmental
    shortening of the critical period versus reversible in adulthood, and what
    is the treatment window for the emerging SYNGAP1-upregulating and gene
    therapies?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Premature Excitatory Synapse and Dendritic Spine Maturation
  - pathophysiology#Impaired Cognitive Development
  rationale: >-
    SynGAP paces synaptic maturation, and its loss causes premature spine
    maturation that shortens the developmental critical period, implying an early
    and possibly fixed contribution to intellectual disability. Yet re-expression
    of SynGAP in adult mice improves memory and seizure measures, suggesting some
    deficits remain reversible after development. How much of the human phenotype
    can be recovered by restoring SYNGAP1 dosage after diagnosis, and how wide
    the therapeutic window is, is decisive for the design and timing of the
    antisense-oligonucleotide and gene therapies now entering development.
  evidence:
  - reference: PMID:31025938
    reference_title: "Re-expression of SynGAP protein in adulthood improves translatable measures of brain function and behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Adult restoration of SynGAP protein improved behavioral and electrophysiological measures of memory and seizure."
    explanation: >-
      Demonstrates partial adult reversibility in a mouse model, framing the open
      question of the human treatment window.
  proposed_experiments:
  - experiment_id: exp_syngap1_timed_restoration
    name: Timed SYNGAP1 restoration across development and adulthood
    description: >-
      In a conditional Syngap1 model, restore SynGAP at graded ages and measure
      recovery of network excitability, seizure susceptibility, and
      cognitive/behavioral endpoints as a function of restoration age.
    experiment_type:
      preferred_term: timed gene-restoration experiment
    readouts:
    - name: Recovery by restoration age
      target: pathophysiology#Impaired Cognitive Development
      assays:
      - preferred_term: behavioral assay
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Never-restored and wild-type
      description: Matched never-restored mutants and wild-type controls.
    decision_criterion: >-
      A treatment window is supported if recovery declines with later restoration
      age; broad reversibility is supported if late restoration still rescues
      endpoints.
    would_support:
    - pathophysiology#Impaired Cognitive Development

- discussion_id: gap_syngap1_dosage_upregulation_therapy
  prompt: >-
    Can boosting expression of the single functional SYNGAP1 allele (an
    upregulating antisense-oligonucleotide or gene-therapy strategy) restore
    sufficient SynGAP to be disease-modifying, and how precisely must dosage be
    controlled given the gene's dosage sensitivity?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  attaches_to:
  - pathophysiology#SYNGAP1 Haploinsufficiency
  rationale: >-
    SYNGAP1 disease is a haploinsufficiency: one functional copy is not enough.
    Because too little SynGAP causes disease, therapies that upregulate the
    remaining allele or add gene copies are attractive and are entering
    development, but SynGAP dosage is tightly constrained, and overshooting could
    have its own consequences. Whether dosage can be restored into a therapeutic
    range, and what biomarker confirms it, is the open translational question for
    this actively developing pipeline.
  evidence:
  - reference: PMID:39807402
    reference_title: "Roadmap to advance therapeutics for SYNGAP1-related disorder: a patient organization perspective from SynGAP Research Fund."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "one of many rare monogenic brain disorders without disease-modifying treatments"
    explanation: >-
      Frames the current absence of disease-modifying therapy and the active
      dosage-restoration pipeline that this hypothesis concerns.
  proposed_experiments:
  - experiment_id: exp_syngap1_dosage_restoration_window
    name: SYNGAP1 dosage-restoration therapeutic window
    description: >-
      In patient iPSC-derived neurons and Syngap1 mice, titrate SYNGAP1
      upregulation and measure the relationship between restored SynGAP level and
      normalization of synaptic and network phenotypes, defining the effective
      and safe dosage range.
    experiment_type:
      preferred_term: dosage-titration experiment
    readouts:
    - name: Phenotype normalization versus SynGAP level
      target: pathophysiology#SYNGAP1 Haploinsufficiency
      assays:
      - preferred_term: multielectrode array recording
      - preferred_term: immunoblot assay
      direction: POSITIVE
    controls:
    - name: Untreated haploinsufficient and wild-type
      description: Matched untreated mutant and wild-type references.
    decision_criterion: >-
      An upregulation strategy is supported if restoring SynGAP toward normal
      levels normalizes synaptic and network phenotypes within a controllable
      dosage range.
    would_support:
    - pathophysiology#SYNGAP1 Haploinsufficiency

- discussion_id: gap_syngap1_mechanism_to_phenotype
  prompt: >-
    Which downstream consequence of SynGAP loss (excitatory synapse
    over-strengthening, AMPA-receptor mis-trafficking, or inhibitory-circuit
    involvement) drives which arm of the phenotype - the generalized epilepsy,
    the intellectual disability, and the autism - and does the consistent
    developmental-delay-before-seizures sequence reflect distinct mechanisms?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cortical Excitation-Inhibition Imbalance
  - pathophysiology#Impaired Cognitive Development
  rationale: >-
    SynGAP haploinsufficiency perturbs excitatory synapse maturation,
    AMPA-receptor trafficking, and circuit excitation/inhibition balance, and the
    disorder combines epilepsy, intellectual disability, and autism. Developmental
    delay reliably precedes seizure onset. Whether these features share one
    substrate or arise from separable mechanisms - and whether targeting one
    (e.g., normalizing excitatory strength) would help all three - is unresolved
    and shapes what a therapy should be measured against.
  evidence:
  - reference: PMID:30541864
    reference_title: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy."
    explanation: >-
      Characterizes the distinctive combined phenotype whose mechanistic
      partitioning is the open question.
  proposed_experiments:
  - experiment_id: exp_syngap1_celltype_specific_contributions
    name: Cell-type-specific contributions to epilepsy versus cognition
    description: >-
      Using cell-type-restricted Syngap1 manipulation (excitatory neurons versus
      interneurons), test which population's dysfunction produces the seizures
      versus the cognitive and autistic phenotypes.
    experiment_type:
      preferred_term: cell-type-restricted manipulation experiment
    readouts:
    - name: Phenotype by targeted cell type
      target: pathophysiology#Cortical Excitation-Inhibition Imbalance
      assays:
      - preferred_term: electroencephalography
      - preferred_term: behavioral assay
      direction: POSITIVE
    controls:
    - name: Pan-neuronal and wild-type
      description: Pan-neuronal manipulation and wild-type as references.
    decision_criterion: >-
      A feature is assigned to a cell type if restricting the SynGAP deficit to
      that population reproduces it while sparing the others.
    would_support:
    - pathophysiology#Cortical Excitation-Inhibition Imbalance
references:
- reference: PMID:30789692
  title: "SYNGAP1-Related Intellectual Disability."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:30789692

SYNGAP1-Related Intellectual Disability.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

SYNGAP1-Related Developmental and Epileptic Encephalopathy — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-4-8 30 citations 2026-07-18T07:29:27.157806

SYNGAP1-Related Developmental and Epileptic Encephalopathy — Comprehensive Research Report

A quick orientation before we dive in, because this disease is a bit of a naming hydra: what the clinic now calls SYNGAP1-related developmental and epileptic encephalopathy (SYNGAP1-DEE) is the same entity that OMIM still files under the dusty old label "mental retardation, autosomal dominant 5 (MRD5)." Same gene, same kids, three decades of shifting vocabulary. Think of it like a river that's been renamed by every town it passes through — I'll flag the aliases as we go so the knowledge-base entry can carry them all.

Evidence-hygiene note for the curator (you, Harry): PMIDs I pulled directly from the searches are marked ✓. A handful of foundational mechanism papers I'm citing from background knowledge are marked ⚠︎VERIFY — run just fetch-reference PMID:XXXX on those before any snippet goes into a YAML, per the project's DR-hallucination SOP. I've kept quotes as exact strings from the abstracts I actually fetched.

1. Disease Information

What it is. SYNGAP1-DEE is a monogenic synaptopathy — a disease of the synapse, the little chemical handshake between neurons — caused by having only one working copy of the SYNGAP1 gene (haploinsufficiency). Clinically it's a near-obligate triad: developmental delay/intellectual disability (essentially 100%), generalized epilepsy (~84–92%), and autism/behavioral–sensory abnormalities (~57–68%), layered on early hypotonia (floppiness) and a distinctive, hard-to-treat epilepsy syndrome. Developmental delay almost always shows up first, in the first months to ~2 years of life, and seizures arrive later — a temporal signature that matters diagnostically (Vlaskamp et al. 2019, Neurology, PMID:30541864 ✓).

Key identifiers (from GenCC/OMIM/Orphanet/MalaCards searches): - Gene: SYNGAP1, HGNC:11497, locus 6p21.32 - OMIM disease: #612621 — "Intellectual developmental disorder, autosomal dominant 5; MRD5" - MONDO: MONDO:0012960 (intellectual developmental disorder, autosomal dominant 5); the "SYNGAP1-related developmental and epileptic encephalopathy" concept is also carried by NORD/Orphanet — worth confirming the exact MONDO with runoak since there may be a newer DEE-specific term - Orphanet: ORPHA:544254 - ICD-10: G40.4 (generalized epilepsy) / F79 for the ID axis; ICD-11: LD90.Y (per search) - MeSH: no dedicated descriptor; indexed under Intellectual Disability + Epilepsies, Generalized + SYNGAP1 supplementary concept

Synonyms / alternative names: SYNGAP1-related intellectual disability; SYNGAP1-ID; MRD5; mental retardation, autosomal dominant 5; SYNGAP1 encephalopathy; SYNGAP1-related nonsyndromic ID with epilepsy; SYNGAP1 syndrome (advocacy usage, CureSYNGAP1).

Data provenance. The knowledge base here should draw on aggregated disease-level sources — GeneReviews (NBK537721), Orphanet, and published cohort/registry studies — rather than individual EHR. The two big modern denominators are the SynGAP Research Fund / Ciitizen digital natural-history registry (147 patients, Wiltrout et al. 2024, Epilepsia, PMC12375243 ✓) and the Vlaskamp 2019 international cohort (57 patients, PMID:30541864).

2. Etiology

Primary cause — genetic, monogenic. Heterozygous loss-of-function (LoF) variants in SYNGAP1, or 6p21.32 microdeletions encompassing the gene. The overwhelming majority are de novo (a fresh mutation in the child, not inherited) — this was the founding observation (Hamdan et al. 2009, NEJM 360:599–605, PMID:19196676 ✓; Hamdan et al. 2011, PMID:21237447 ✓). The disease mechanism is dosage — you need two full servings of SynGAP protein and one isn't enough; there's no rescuing spare.

Risk factors. - Genetic: The causal variant IS the risk factor; because it's de novo, classic "susceptibility loci / modifier genes" don't drive occurrence. Advanced parental age is a weak generic contributor to de novo mutation rates (not SYNGAP1-specific). - Environmental / lifestyle / occupational: None established. This is a "bad luck at conception" disorder, not an exposure disorder. No toxin, infection, diet, or occupational link.

Protective factors. No genetic or environmental protective factors are established in humans. Mechanistically interesting caveat from mouse work: the disease is developmental-timing-sensitive, so the "protective" lever is when you restore protein, not any exogenous exposure (see §6/§15).

Gene–environment interactions. Not applicable in the conventional sense. The one real "×environment" axis is seizure triggers: eating and eye-closure provoke reflex seizures in a substantial minority (~25% eating-triggered; Vlaskamp 2019) — an interaction between the genetic substrate and sensory/behavioral state, not toxicology.

3. Phenotypes

The phenotype is a generalized DEE plus a neurodevelopmental disorder. Frequencies below are anchored to the 147-patient registry (Wiltrout 2024 ✓) and the 57-patient Vlaskamp cohort (2019 ✓).

Neurodevelopmental / cognitive - Global developmental delay / intellectual disability — HP:0001263 / HP:0001249. Frequency ~100% ("All patients were diagnosed with global developmental delay (GDD) and/or ID"). Usually moderate–severe, occasionally mild. Onset: infancy; precedes seizures. Course: developmental plateau between ~2 and 5 years, possibly epilepsy-modulated (Kim et al. 2024, AJMG-A, PMID:38563110 ✓). - Absent/impaired speech — HP:0001344 / HP:0000750. Genotype-linked: "83% of individuals with variants in exons 1–4 were able to speak in phrases vs 31% of individuals with variants in exons 5–19" (Wiltrout 2024 ✓). - Autism spectrum disorder / autistic behavior — HP:0000717 / HP:0000729. ~57–68%. - Behavioral problems (HP:0000708) ~68%; anxiety (HP:0000739); aggression/impulsivity.

Epilepsy (the DEE core) — HP:0011097 (generalized), HP:0002133 (status), HP:0002123 (generalized myoclonic) - Generalized epilepsy overall ~84–92%; "Of the 57 patients, 56 had epilepsy: generalized in 55" (Vlaskamp 2019 ✓). - Eyelid myoclonia with absences — HP:0032648 (eyelid myoclonia) / HP:0002121 (absence). ~65% — the signature semiology. - Myoclonic seizures — HP:0032794/HP:0002123. ~34%. - Atypical absences HP:0007270 ~20%; typical absences HP:0011147 ~18%. - Atonic / drop attacks — HP:0010819. ~14%; a novel semiology described as "eyelid myoclonia evolving to a myoclonic-atonic or atonic seizure." - Reflex seizures triggered by eating — ~25%; and by eye closure. - Epilepsy syndromic overlap: myoclonic-atonic epilepsy (Doose), epilepsy with eyelid myoclonia (Jeavons-like), epilepsy with myoclonic absences. - Onset: median ~2 years (Vlaskamp) to 31–34 months (registry), range ~4 months–7 years. Course: often refractory and evolving — up to ~35% show semiology evolution; EEG shifts from occipital → frontal discharges with age (Frontiers/Kim EEG study 2024).

Motor / tone - Hypotonia — HP:0001252 (early, prominent). Ataxia / abnormal gait — HP:0001251 / HP:0001288, ~47%. Unstable/wide-based gait.

Systemic / other - Sleep problems — HP:0002360, ~61%. - Feeding difficulties — HP:0011968, ~47%; oral-motor dysfunction, drooling. - Constipation / GI dysmotility — HP:0002019. - High pain threshold / abnormal pain sensitivity and strabismus (HP:0000486) reported. - Behavioral/sensory abnormalities (sensory-seeking) frequently noted.

Quality-of-life impact. Severe and pervasive: most affected individuals are non- or minimally-verbal, need lifelong supervision, and the combination of refractory seizures + autism + sleep disruption drives heavy caregiver burden. No SYNGAP1-specific EQ-5D/SF-36 dataset exists; QoL is captured qualitatively in registry/advocacy work (Graglia et al. 2025 roadmap, PMID:39807402 ✓).

Genotype–phenotype summary: variants toward the 5′ end (exons 1–6) trend milder for ID/ASD but carry higher refractory-epilepsy risk; SH3-binding-motif variants show lower epilepsy frequency (Hong et al. 2025, Clin Genet; Wiltrout 2024 ✓).

4. Genetic / Molecular Information

Causal gene. SYNGAP1 (synaptic Ras-GTPase-activating protein 1), HGNC:11497, chromosome 6p21.32, ~19 exons, multiple C-terminal isoforms (α1, α2, β, γ). OMIM gene 603384; disease 612621.

Pathogenic variants. - Type/class: predominantly loss-of-function — nonsense, frameshift, canonical splice-site, and a smaller share of missense (often clustering in the C2/GAP catalytic domain). Whole-gene/6p21.32 microdeletions (CNVs) also cause it. LoF-intolerant gene (very high pLI in gnomAD). - ACMG classification: the vast majority are pathogenic/likely pathogenic; truncating de novo variants meet PVS1+PS2. VUS are typically missense. - Allele frequency: essentially absent from population databases (gnomAD) — consistent with a highly penetrant, de novo, LoF disorder. - Origin: germline, de novo in the overwhelming majority; rare inherited cases from a mildly affected or mosaic parent exist (relevant to recurrence counseling). - Functional consequence: haploinsufficiency (loss of function, dosage). Not a classic dominant-negative for truncating alleles, though some C-terminal isoform-specific variants may perturb splice-form balance (Endogenous Syngap1 α splice forms, eLife 2022).

Modifier genes. None validated; residual phenotypic variance is attributed to variant position/isoform impact rather than a mapped modifier.

Epigenetics. No established disease-driving DNA-methylation or histone signature. (A reproducible "episignature" for SYNGAP1 has not been robustly reported the way it has for some other NDD genes — an open question, not an established feature.)

Chromosomal abnormalities. 6p21.32 microdeletions spanning SYNGAP1 are a recognized cause; detectable by chromosomal microarray. Contiguous-gene deletions can add extra features beyond the core phenotype.

Ontology anchors: gene → HGNC:11497; suggest GO/CL/UBERON terms in §6–§7.

5. Environmental Information

Environmental factors: none — no toxin, radiation, pollution, or occupational contribution to disease causation.
Lifestyle factors: none causal. Diet is relevant only therapeutically (ketogenic diet, §12) and as a seizure trigger (eating-induced reflex seizures).
Infectious agents: none — not an infectious or post-infectious disease.

This section is genuinely not applicable as an etiologic axis; SYNGAP1-DEE is purely genetic.

6. Mechanism / Pathophysiology

Here's where the biology gets gorgeous. Picture the excitatory synapse's postsynaptic density (PSD) as a crowded loading dock. SynGAP is one of the most abundant proteins on that dock — a Ras/Rap GTPase-activating protein tethered to the NMDA-receptor complex via PSD-95. Its day job is to keep the Ras→ERK/MAPK and Rap signaling switches turned off until a legitimate calcium signal (through the NMDA receptor + CaMKII) says "go." SynGAP is thus a brake on synaptic strengthening (Frontiers "SYNGAP1: Mind the Gap," PMID:26912996 ✓).

The causal chain (upstream → downstream):

Trigger — SynGAP haploinsufficiency. ~50% less SynGAP protein at the PSD.
Dysregulated small-GTPase signaling. Loss of GAP activity → constitutively elevated Ras-GTP → hyperactive ERK/MAPK, plus disturbed Rap signaling. The brake is half-off. (GO:0032312 regulation of ARF/Ras GTPase activity; GO:0007265 Ras signal transduction; GO:0000186 activation of MAPKK activity.)
Aberrant AMPA-receptor trafficking. Excess Ras/ERK drives premature insertion of AMPA receptors into the postsynaptic membrane, increasing excitatory synaptic strength too early. (GO:0032281 AMPA glutamate receptor complex; GO:0098976 excitatory chemical synaptic transmission.)
Precocious dendritic-spine maturation. Spines "grow up too fast," shortening the critical window of plasticity — the developmental period when circuits are supposed to stay malleable (Clement et al. 2012, Cell 151:709–723 ⚠︎VERIFY PMID:23141539; critical-period paper, PMC4326604). (GO:0060997 dendritic spine morphogenesis; GO:0050803 regulation of synapse structure/activity.)
Circuit-level E/I imbalance. "Early hard-wiring" of cortical and thalamocortical circuits → excitation/inhibition imbalance, abnormal cortical oscillations, and impaired plasticity → the substrate for both cognitive impairment and generalized seizures (synaptic-neoteny study, Neuron 2024).
Clinical manifestation. ID + generalized epilepsy + autistic/behavioral features.

This maps cleanly onto your existing epilepsy_excitation_inhibition_imbalance module — the conserved chain "ion-channel/synaptic dysfunction → E/I imbalance → hyperexcitability/hypersynchrony → seizures." SYNGAP1-DEE is a near-textbook synaptic (rather than ion-channel) conformer of epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance. Worth a conforms_to edge.

Protein dysfunction: loss of a PSD scaffold-associated enzyme → downstream signaling deregulation (not aggregation/misfolding). UniProt Q96PV0 (SYNGAP1_HUMAN).

Cellular processes / cell types: the disorder is intrinsic to excitatory glutamatergic cortical/hippocampal pyramidal neurons (CL:0000598 pyramidal neuron; CL:0000679 glutamatergic neuron; CL:0000617/CL:0000540 neuron), with interneuron-circuit consequences. Subcellular: the postsynaptic density of the dendritic spine (GO:0014069 postsynaptic density; GO:0043197 dendritic spine).

Metabolic / immune / fibrosis / oxidative: none primary — this is not a metabolic, autoimmune, or degenerative disease.

Molecular profiling / advanced tech: human xenotransplanted cortical neuron and iPSC models show disrupted "synaptic neoteny" (the human-specific slow synapse maturation), tying SynGAP loss to accelerated human-neuron maturation (Neuron 2024). Mouse cortical CRISPR/functional-genomics and re-expression studies underpin the reversibility work (§15). No disease-defining metabolomic/proteomic biomarker panel exists yet.

7. Anatomical Structures Affected

Organ / system: central nervous system (UBERON:0001017), specifically cerebral cortex (UBERON:0000956) and hippocampus (UBERON:0002421); thalamocortical circuitry implicated. Body system: nervous system (predominant); secondary GI dysmotility (enteric nervous system) and no primary cardiac/renal/hepatic involvement.
Tissue / cell: gray-matter neural tissue; excitatory glutamatergic pyramidal neurons (CL:0000598) are the primary affected population; downstream inhibitory-interneuron circuit dysfunction.
Subcellular: postsynaptic density (GO:0014069) of dendritic spines (GO:0043197) on excitatory synapses (GO:0060076); the NMDA-receptor/PSD-95 signaling complex.
Localization / laterality: bilateral, diffuse/generalized cortical involvement (consistent with generalized epilepsy and global ID); brain MRI is usually normal or nonspecific — this is a functional/microstructural, not gross-structural, disorder.

8. Temporal Development

Onset: congenital/infantile for the neurodevelopmental axis — hypotonia and developmental delay in the first months to ~2 years, before seizures. Epilepsy onset median ~2 years (range ~4 months–7 years).
Pattern: chronic, largely static-to-plateauing developmental course rather than frank neurodegeneration; a notable plateau/relative regression window at ~2–5 years (Kim 2024 ✓).
Epilepsy course: frequently drug-resistant and evolving — semiology and EEG change over childhood (occipital→frontal discharge migration; eyelid myoclonia → myoclonic → atonic evolution in ~35%).
Remission: seizures may improve in some by adolescence/adulthood but ID and autism persist lifelong; spontaneous remission of the disorder does not occur.
Critical period: the animal data make this the therapeutically pivotal concept — an embryonic/early-postnatal developmental window during which circuit assembly is derailed, with implications for the timing of any disease-modifying therapy (§15).

9. Inheritance and Population

Inheritance. Autosomal dominant, HP:0000006; nearly always de novo. Penetrance essentially complete for the LoF variants; expressivity variable (severity tracks variant position/isoform). No anticipation (not a repeat-expansion disorder). Germline/somatic mosaicism in a parent is a real, if uncommon, recurrence mechanism → warrants parental testing and counseling. No founder effects, no consanguinity role, no carrier-frequency concept (it's not a recessive/carrier disease).

Epidemiology. Prevalence figures diverge sharply by source and this is worth flagging in the KB: - Orphanet lists <1/1,000,000 as a documented point prevalence — almost certainly an underestimate (SYNGAP1 is widely regarded as under-diagnosed, CureSYNGAP1). - Yield-based estimates are much higher: ~1% of epileptic encephalopathy cohorts and ~0.75% of unexplained ID cohorts carry pathogenic SYNGAP1 variants (GeneReviews NBK537721; Vlaskamp 2019 ✓). Some reviews put the population incidence at 1–4/10,000, i.e. ~0.5–4% of ID, making it one of the more common single-gene causes of ID-with-epilepsy. - Curation guidance: record the coarse band honestly — the true population prevalence is genuinely uncertain; the diagnostic yield numbers (~1% of DEE, ~0.75% of ID) are the more defensible, better-sourced claims. In your Prevalence schema I'd use measure_type: POINT_PREVALENCE, prevalence_class for the Orphanet band, but lean on the yield statistics in notes with their cohort context.

Demographics. No ethnic predilection; global distribution (de novo). Sex ratio ~1:1 (50% male in both the 147- and 57-patient cohorts). Age distribution: pediatric-diagnosed, lifelong condition; adult cases increasingly recognized via reanalysis (adult WES "cold case," PMC10617251).

10. Diagnostics

The diagnosis is genetic. There is no biochemical or imaging test that makes it — those support and exclude.

Genetic testing (definitive): - First-line: broad genomic testing — exome (WES) or genome (WGS), or a DEE/ID multigene panel that includes SYNGAP1. High-yield in the "developmental delay → later generalized epilepsy" phenotype. - Chromosomal microarray (CMA): catches 6p21.32 microdeletions that sequencing panels can miss. - Single-gene testing / targeted variant analysis: for family cascade or confirming a specific variant. - Parental testing: to establish de novo status and screen for mosaicism (recurrence risk). - Karyotype/FISH/mtDNA/repeat-expansion testing: low yield / not indicated for the typical presentation.

Supportive / phenotyping tests: - EEG (the key functional test): generalized (poly)spike-wave, often with eyelid-myoclonia-associated discharges, photosensitivity, eating/eye-closure-triggered discharges; occipital→frontal shift with age. EEG is central to characterizing the epilepsy but is not specific. - Brain MRI: usually normal/nonspecific — its main value is ruling out structural mimics. - Developmental / neuropsychological assessment, autism evaluation (ADOS/ADI-R), sleep evaluation. - No validated blood/CSF biomarker exists.

Clinical criteria & differential. No formal consensus criteria; diagnosis rests on genotype + compatible phenotype. Differential diagnosis (the "generalized DEE with myoclonic/absence/atonic seizures + ID" neighborhood): Dravet syndrome (SCN1A), Doose/myoclonic-atonic epilepsy, Jeavons syndrome (eyelid myoclonia with absences), Lennox-Gastaut syndrome, Angelman syndrome (UBE3A), STXBP1-, SLC6A1-, GABA-pathway DEEs, and KANSL1/other ID-with-epilepsy genes. Distinguishing feature: developmental delay clearly preceding seizure onset, plus the eyelid-myoclonia/eating-triggered semiology.

Screening. Not on newborn-screening panels; no carrier screening (de novo dominant). Ascertainment is via diagnostic genomic testing in ID/DEE, and increasingly via exome/genome reanalysis of previously undiagnosed patients — a real-world driver of the "under-diagnosed" story.

11. Outcome / Prognosis

Survival / mortality: Life expectancy is generally not markedly shortened, and it is not a primarily lethal disorder; however, like other refractory DEEs it carries an elevated risk of SUDEP (sudden unexpected death in epilepsy) and seizure/status-related and aspiration-related morbidity. No robust disease-specific mortality rate is published.
Morbidity / function: high lifelong disability — most individuals are non-/minimally verbal, dependent for daily activities, and require lifelong support. Autism, sleep disruption, and behavioral challenges compound the ID.
Disease course / complications: refractory epilepsy, injury from atonic drop attacks, feeding/aspiration issues, constipation, sleep disorder, behavioral crises.
Recovery potential: the ID/autism axis is stable and permanent with current care; seizures are often refractory but may attenuate over time in some. No spontaneous recovery.
Prognostic factors: variant position/isoform and epilepsy severity/refractoriness are the main prognostic levers (e.g., 5′/exon-1–4 variants → better language outcomes; refractory epilepsy → worse developmental trajectory). No validated prognostic biomarker beyond genotype.
QoL measures: no SYNGAP1-specific instrument; generic pediatric-NDD and caregiver-burden tools are used in registry/advocacy contexts.

12. Treatment

Bottom line: no disease-modifying therapy is approved yet — care is symptomatic — but the precision-medicine pipeline is unusually active (Graglia et al. 2025 roadmap, PMID:39807402 ✓).

Antiseizure medications (mainstay; MAXO:0000058 pharmacotherapy / MAXO:0000630 pharmacotherapy): - Broad-spectrum ASMs favored for generalized/myoclonic seizures: valproate, lamotrigine, levetiracetam, ethosuximide (for absences), clobazam, and cannabidiol (Epidiolex) — the latter with reported benefit in SYNGAP1-associated refractory/myoclonic-atonic epilepsy (CBD in MAE, Epileptic Disorders 2025). - Caution: as with other generalized epilepsies, sodium-channel blockers (e.g., carbamazepine/phenytoin) can worsen myoclonic/absence seizures. - Ketogenic diet (MAXO:0001056 / dietary intervention MAXO:0000088) — used in refractory cases with anecdotal benefit.

Supportive / rehabilitative (large share of real-world management): - Speech-language therapy, occupational therapy, physical therapy (MAXO:0000011 physical therapy; MAXO:0000020-class rehabilitation), AAC (augmentative communication) devices. - Behavioral/ASD interventions, sleep management (melatonin), feeding/GI management, genetic counseling (MAXO:0000079).

Investigational / disease-modifying pipeline (the exciting part): - Antisense oligonucleotides (ASOs): the leading modality. CAMP4 Therapeutics' CMP-SYNGAP-01 — an intrathecal ASO that upregulates SYNGAP1 expression (a "regulatory RNA"/upregulation approach rather than knockdown) — entered GLP toxicology in Oct 2025, with a Phase 1/2 first-in-human start targeted for 2H 2026 (CAMP4 announcement). Multiple companies + academic groups have ASO and AAV programs in pipelines (roadmap PMID:39807402 ✓). - AAV gene therapy: preclinical AAV delivery of full-length SYNGAP1 rescued epileptic and behavioral phenotypes in mice (Molecular Therapy 2025) — proof-of-concept for gene supplementation. - Discontinued for the class: soticlestat (TAK-935), a cholesterol-24-hydroxylase inhibitor trialed across DEEs, was discontinued by Takeda in 2025 after Phase 3 misses in Dravet/LGS (Takeda statement) — it was never SYNGAP1-specific. - Other explored approaches: taurine supplementation and ketogenic diet (anecdotal); ERK/MAPK-pathway modulation is a rational target given the mechanism but not clinically validated.

Pharmacogenomics / personalized medicine: the whole point of the ASO/AAV work is genotype-directed dosage restoration; ASO eligibility is being formally assessed for SYNGAP1 among infantile genetic epilepsies (medRxiv 2025).

Treatment strategy: individualized ASM selection for generalized/myoclonic semiology + aggressive developmental/behavioral support; enrollment in the SYNGAP1/Brain Gene Registry and natural-history studies to be trial-ready (Brain Gene Registry, PMID:40282364 ✓).

13. Prevention

Primary prevention: not possible — de novo dominant mutation; no modifiable exposure. Only reproductive options apply for a family with an identified proband: prenatal diagnosis or preimplantation genetic testing (PGT-M) in the rare inherited/mosaic-parent scenario, and recurrence-risk counseling (empirically low but non-zero due to possible parental germline mosaicism).
Secondary prevention (early detection → early intervention): the actionable lever. Early genomic diagnosis (broad WES/WGS in ID/DEE, plus exome reanalysis) enables early developmental therapy and trial-readiness — and, if disease-modifying therapy arrives, the developmental critical period makes early treatment potentially decisive.
Tertiary prevention (complication reduction): seizure control to limit injury/SUDEP, aspiration/nutrition management, sleep and behavioral support, physical/OT to preserve function.
Immunization / public-health / environmental measures: not applicable (not infectious/environmental).
Genetic counseling (MAXO:0000079) is the central preventive-medicine service: de novo status confirmation, mosaicism screening, and family-planning guidance.

14. Other Species / Natural Disease

Taxonomy of the ortholog: SYNGAP1 is deeply conserved across vertebrates — human NCBITaxon:9606, mouse Syngap1 (NCBITaxon:10090, MGI), rat (NCBITaxon:10116), zebrafish (NCBITaxon:7955, ZFIN).
Naturally occurring disease in animals: none catalogued — there is no spontaneous companion-animal or livestock SYNGAP1 disease in OMIA; all animal disease is engineered (see §15). So this is genuinely not applicable as a "natural disease of other species."
Comparative biology / evolutionary conservation: the NMDAR–SynGAP–Ras/ERK–AMPAR synaptic module is highly conserved, which is why rodent models translate mechanistically. A striking human-specific twist: "synaptic neoteny" (protracted human synapse maturation) is disrupted by SynGAP loss in xenotransplanted human neurons — a conservation-with-a-human-difference story (Neuron 2024).
Zoonotic potential / cross-species transmission: not applicable (genetic, non-transmissible).

15. Model Organisms

The model story is the crown jewel here, because it delivered the field's central hope: the disorder may be at least partly reversible even after development.

Mouse (Syngap1^+/− heterozygous knockout) — the workhorse (MGI). Recapitulates cognitive deficits, autistic-like behaviors, and epilepsy/interictal spiking (comprehensive behavioral analysis, PMC7292322). Homozygous null is embryonic-lethal — consistent with dosage-critical function.
Critical-period / developmental-timing models: Syngap1 haploinsufficiency "damages a postnatal critical period of pyramidal cell structural maturation linked to cortical circuit assembly" (PMC4326604). Conditional/temporal genetic-rescue experiments show full protection when the gene is restored in cortical progenitors mid-to-late embryonically, but limited benefit from CNS-wide reversal begun in adulthood — establishing a developmental window.
Adult-reversal models (the therapeutic-optimism papers): "Re-expression of SynGAP protein in adulthood improves translatable measures of brain function and behavior" (Creson/Rumbaugh et al., eLife 2019) — adult restoration improved memory measures and eliminated sleep-worsened interictal events. So: development sets the ceiling, but adult intervention still moves meaningful endpoints — the biological rationale for ASO/gene therapy in already-diagnosed children and adults.
Isoform models: endogenous α-splice-form manipulation shows specific isoforms promote cognition and seizure protection (eLife 2022) — relevant to designing expression-restoring therapeutics.
Gene-therapy proof-of-concept: AAV full-length SYNGAP1 rescued epileptic and behavioral phenotypes in the mouse model (Molecular Therapy 2025).
Human cellular models: iPSC-derived neurons, cortical organoids, and xenotransplanted human cortical neurons — reveal disrupted synaptic neoteny/maturation (Neuron 2024); ideal for evidence_source: IN_VITRO. Other systems: rat, zebrafish, and Drosophila orthologs exist for pathway work.
Model limitations: mouse heterozygotes under-model the full human seizure severity (interictal spikes ± occasional seizures rather than the florid human eyelid-myoclonia/absence syndrome); and the human-specific neoteny biology can't be captured in rodent neurons — a genuine HUMAN_MODEL_MISMATCH candidate for your KB (evidence exists in models, but translational fidelity of the seizure phenotype and the human-maturation timeline is the open question).

Curation notes for the dismech entry

Module conformance: strong conforms_to: epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance — SYNGAP1-DEE is a clean synaptic (non-channel) conformer. The mechanistic chain in §6 gives you the trigger→consequence nodes.
HUMAN_MODEL_MISMATCH discussion: the mouse-vs-human seizure-severity gap and the human synaptic-neoteny biology are worth a kind: HUMAN_MODEL_MISMATCH discussion, not a generic knowledge gap — evidence exists in models, fidelity is the question.
Prevalence honesty: curate the Orphanet <1/1,000,000 band but foreground the ~1% of DEE / ~0.75% of ID yield statistics with cohort context in notes; note explicit under-diagnosis.
Genotype–phenotype: the exon-1–4 vs exon-5–19 language split and the 5′/refractory-epilepsy trade-off are quotable, well-sourced, and belong in genetic/subtype notes.
⚠︎VERIFY before snippeting: re-fetch PMIDs I cited from background memory (Clement 2012 Cell ~PMID:23141539; eLife 46752/75707; PMC4326604 — confirm authors/year) with just fetch-reference and confirm exact abstract substrings. The ✓-marked PMIDs (19196676, 21237447, 30541864, 38563110, 39807402, 40282364) came straight from the searches and the two fetched abstracts (PMC6340340, PMC12375243) gave verbatim quotes you can lift directly.

Sources: - Vlaskamp et al. 2019, Neurology — SYNGAP1 encephalopathy: a distinctive generalized DEE (PMID:30541864) - Wiltrout et al. 2024, Epilepsia — Comprehensive phenotypes of SYNGAP1-related disorder (147 patients) - Kim et al. 2024, Am J Med Genet A — genotype/phenotype & longitudinal insights (PMID:38563110) - Hamdan et al. 2009, NEJM — Mutations in SYNGAP1 in nonsyndromic MR (PMID:19196676) - Hamdan et al. 2011 — De novo SYNGAP1 mutations in nonsyndromic ID and autism (PMID:21237447) - GeneReviews — SYNGAP1-Related Intellectual Disability (NBK537721) - Orphanet — SYNGAP1-related DEE (ORPHA:544254) - OMIM #612621 — MRD5 - Frontiers — "SYNGAP1: Mind the Gap" (PMID:26912996) - Clement et al. 2012, Cell — pathogenic SYNGAP1 mutations & dendritic-spine maturation - Creson/Rumbaugh et al. 2019, eLife — adult re-expression of SynGAP - Critical-period damage paper, PMC4326604 - Endogenous Syngap1 α splice forms, eLife 2022 - AAV full-length SYNGAP1 rescue, Molecular Therapy 2025 - SYNGAP1 deficiency disrupts synaptic neoteny, Neuron 2024 - Graglia et al. 2025 — SynGAP Research Fund therapeutics roadmap (PMID:39807402) - SYNGAP1 Syndrome and the Brain Gene Registry, 2025 (PMID:40282364) - CAMP4 CMP-SYNGAP-01 GLP toxicology announcement, Oct 2025 - Takeda soticlestat (TAK-935) discontinuation, 2025 - Comprehensive behavioral analysis of heterozygous Syngap1 KO mice, PMC7292322 - Hong et al. 2025, Clinical Genetics — genotype–phenotype correlations in MRD5

SYNGAP1-Related Developmental and Epileptic Encephalopathy

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Related Datasets

Source YAML

References & Deep Research

References

Deep Research

SYNGAP1-Related Developmental and Epileptic Encephalopathy — Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation notes for the dismech entry